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Abstract
Sequence-specific binding by the human p53 master regulator is critical to its tumor suppressor activity in response to
environmental stresses. p53 binds as a tetramer to two decameric half-sites separated by 0–13 nucleotides (nt), originally
defined by the consensus RRRCWWGYYY (n=0–13) RRRCWWGYYY. To better understand the role of sequence, organization,
and level of p53 on transactivation at target response elements (REs) by wild type (WT) and mutant p53, we deconstructed
the functional p53 canonical consensus sequence using budding yeast and human cell systems. Contrary to early reports on
binding in vitro, small increases in distance between decamer half-sites greatly reduces p53 transactivation, as
demonstrated for the natural TIGER RE. This was confirmed with human cell extracts using a newly developed, semi–in
vitro microsphere binding assay. These results contrast with the synergistic increase in transactivation from a pair of weak,
full-site REs in the MDM2 promoter that are separated by an evolutionary conserved 17 bp spacer. Surprisingly, there can be
substantial transactivation at noncanonical K-(a single decamer) and L-sites, some of which were originally classified as
biologically relevant canonical consensus sequences including PIDD and Apaf-1. p53 family members p63 and p73 yielded
similar results. Efficient transactivation from noncanonical elements requires tetrameric p53, and the presence of the
carboxy terminal, non-specific DNA binding domain enhanced transactivation from noncanonical sequences. Our findings
demonstrate that RE sequence, organization, and level of p53 can strongly impact p53-mediated transactivation, thereby
changing the view of what constitutes a functional p53 target. Importantly, inclusion of K- and L-site REs greatly expands
the p53 master regulatory network.
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Introduction
The tumor suppressor p53 (OMIM no. 191170) is a sequence-
specific master regulatory gene that controls an extensive transcrip-
tional network providing for genome integrity in response to
cellular and environmental stresses or damage [1–3]. p53
differentially regulates the expression of target genes, as well as
microRNAs associated with cell cycle control, apoptosis, DNA
repair, angiogenesis, senescence and carbon metabolism [4,5]. A
variety of factors such as stress and cell-type dependent, post-
translation modifications and transcriptional co-factors can
influence p53-induced transcriptional changes [6–8]. Paramount
to p53 transcriptional function is the direct interaction between
p53 and its targeted DNA sequence. The nature of this interaction
could per se determine transactivation capacity, as well as influence
p53-mediated biological processes [9]. Such activities are often
altered during human cancer development as highlighted by the
frequent appearance of p53 missense mutations in its sequence-
specific DNA binding domain [10,11] which can abrogate or alter
p53 transactivational activity that result in changes in biological
responses, such as the balance between apoptosis and survival in
response to DNA damage. [3,10,12–15].
Through in vitro studies, a consensus p53 DNA binding sequence
has been derived comprising a motif of two decamers (half-sites)
RRRCWWGYYY (n) RRRCWWGYYY, (where R=purine,
W=A or T, Y=pyrimidine and n is 0–13 bases) where each
decamer is composed of two adjacent p53 monomer binding sites
(quarter-sites) in inverted orientation [16–18]. p53 binds coopera-
tively to the consensus RE as a dimer of dimers, where a tetramer is
the accepted functional unit required for full transcriptional activity
[19–26]. Most functional response elements (REs) identified in
association with p53 target genes depart from this consensus, where
base changes are tolerated at each position with the exception of the
C and G at positions 4 and 7 in each half-site [27,28].
Recent crystal structures show that the interactions between p53
and DNA are influenced by the base pairs present in the RE
sequence [29] while binding assays in solution established a wide
range of dissociation constants among natural p53 REs [23].
Functional studies in model systems demonstrate that the RE
sequence and amount of p53 expression can dramatically
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RE [3,30]. However, results of those various approaches do not
fully overlap and it is still not well-understood how the loose
consensus, in terms of base variation and spacer length between
half-sites affects p53 binding to DNA, or how differential binding
relates to transactivation specificity [31–33].
More recently, several studies have refined the accepted, or
canonical p53 consensus binding sequence based on presumed
unbiased chromosome- or genome-wide in vivo binding assays
using chromatin immunoprecipitation (ChIP) [34–37]. However,
the findings may be skewed towards stronger p53 interacting
sequences or influenced by the agent used to induce p53 protein,
as well as the human cell lines examined. While ChIP provided a
powerful tool for identifying sequences that p53 could bind and
the results pointed to a refined p53 consensus with more restrictive
sequence features [34], these assays could not address the strength
of p53 binding. Furthermore, the experimental approach failed to
retrieve known p53 binding sites, indicating that the technique
could miss interactions between p53 and weaker response elements
which might include noncanonical sites that do not match the
accepted consensus motif.
Bioinformatics studies to identify p53 REs are guided by
identified sequences. Based on the consensus sequence, computa-
tional algorithms have exploited the base pair composition of
known p53 REs to determine binding probabilities of p53 towards
sequences and generate position-weight matrices (PWM) or
‘‘logos’’ [38,39]. While such algorithms may guide the identifica-
tion of p53 binding sites in the genome, they cannot assess the
strength of p53 binding to these sequences. The ability of p53 to
bind (and presumably transactivate from) a sequence is often
related to compliance with the canonical consensus sequence
where each position in the motif is assumed to be equivalent and
mutually exclusive in terms of affecting p53 binding [40].
However, PWM values appear not to be a good predictor of
p53 transactivation [30].
While the canonical consensus sequence has guided studies of the
p53 network,an additional layer of complexity was identified recently
suggesting that the canonical motif is not limited to two decamers in
human cells. p53 dependent-transactivation was detected in
association with a decamer half-site created by a single nucleotide
polymorphism (SNP)in the promoter of the FLT-1 gene (the vascular
endothelial growth factor (VEGF) receptor-1 gene) [41]. These results
showing that p53 can function from a noncanonical consensus
sequence imply that the number of potential p53 target sites within
the genome may be much greater than anticipated. Current methods
that identify and/or define putative p53 REs would overlook such
noncanonical binding elements.
Stimulated by the observation of a transcriptionally active p53
half-site, as well as by the finding that even a single nucleotide
change can greatly impact transactivation potential of a RE
[42,43], we have systematically deconstructed the canonical p53
RE sequence to address the requirements for a functional p53
binding site. Utilizing in vivo systems we developed in the budding
yeast Saccharomyces cerevisiae, the transactivation potential of p53 was
first examined from p53 canonical consensus REs containing base
changes and/or variations in organization of binding motifs (i.e.,
multiple REs and various spacer lengths) and then assessed
transactivation from K- and L-site REs, which we refer to as
noncanonical REs. For these noncanonical REs the surrounding
sequence does not resemble a p53 binding sequence and the motif
itself would not be recognized within standard descriptions of a
p53 canonical consensus sequence. Within the yeast system, we
have addressed not only the ability of p53 to function from specific
target sequences (i.e., on/off), but also the extent of transactivation
from these sites at variable levels of expression. These studies have
been extended to transactivation capacity and p53 promoter
occupancy in a human cell system, and the in vivo functionality
evaluations were compared with results obtained in a recently
developed semi-in vitro binding assay using human cell nuclear
extracts. Several structural mutants were examined to assess the
p53 structural requirements for transactivation from noncanonical
REs. Overall, the findings expand our understanding, as well as
the anticipated size of the human p53 master regulatory network.
Results
Isogenomic System To Address p53 Transactivation from
REs in Diploid Yeast
Previously, we had developed a plasmid-based haploid yeast
system to systematically evaluate the contribution of RE sequence
and p53 expression level towards p53 differential transactivation
[14,30]. While many factors may ultimately determine p53
transactivation of individual genes in human cells including stress
stimuli, post-translational modifications, and transcriptional cofac-
tors, the yeast system addresses the potential for wild type and mutant
p53 to bind and transactivate from various REs derived from human
genes when placed in a constant chromatin environment.
We have expanded this experimental system to diploid yeast to
further assess the transactivation capacities of p53 (WT or mutant)
(Figure 1A). Two panels of modified S. cerevisiae strains were
generated. The first was a set of p53 host strains in which p53 (WT
or mutant) is directed by a ‘‘rheostatable’’ GAL1 promoter that
allows for controlled, over 200-fold, inducible expression of p53 in
yeast depending on the carbon source in the media (Figure 1B and
Figure S1). Importantly, similar to p53 protein accumulation in
mammalian cells following stress [44], expression from the GAL1
promoter in yeast displays a graded transcriptional response such
that there is a range of activity from the promoter as opposed to a
binary, or on/off response [45–47]. Biggar and Crabtree [45]
demonstrated through fluorescence-activated cell sorting (FACS)
experiments that expression of green fluorescent protein from a
Author Summary
Within human cells, the tumor suppressor p53 is the
central node of regulation required to elicit multiple
biological responses that include cell cycle arrest and
death in response to stress or DNA damage, where
mutations in p53 are a hallmark of cancer. As a master
regulatory gene, p53 controls the action of target genes
within its network by directly interacting with a widely
accepted consensus DNA binding sequence, composed of
two decamer K-sites that can be separated by up to 13
bases. While mismatches from consensus sequence are
frequent, the canonical consensus sequence places a
limitation upon the organization and number of target
genes within the p53 transcriptional network. Using yeast
and human cell systems, our goal was to further
understand how the DNA sequence, DNA organization,
and level of p53 expression might influence the inclusion
of genes within the p53 regulatory network. We found that
increases in spacer beyond a few bases greatly reduce
responsiveness to p53. Importantly, we established that
p53 can function from noncanonical sequences compris-
ing only a decamer K-site or a L-site. These findings
further define and expand the universe of potential
downstream target genes which may be regulated by
p53 and bring further diversity into the p53 regulatory
network.
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fluorescent peak where the intensity of the peak was dependent
upon the concentration of galactose supplemented in the media.
Thus, increases in galactose will result in a homogeneous response
where the vast majority of cells in the population respond (within
our system expressing an induced amount of p53) rather than
merely increasing the percentage of cells within the population
expressing the maximal level of protein.
The second set of strains of opposite mating type contained
promoter REs upstream of the minimal CYC1 promoter and either
the ADE2 color reporter or the firefly luciferase reporter [28]. To
facilitate the construction of a large number of p53 mutants and
REs at chromosomally located target loci we employed the delitto
perfetto system for in vivo mutagenesis. Delitto perfetto utilizes
oligonucleotides and targeted homologous recombination to
rapidly generate S. cerevisiae yeast strains with specific genetic
alterations [48,49].
Mating of the reporter and p53 host strains results in isogenic,
diploid yeast that enable the rapid assessment of the transactiva-
tion potential for WT or mutant p53 proteins towards many
individual REs in the p53 transcriptional network [14]. Impor-
tantly, all the conditions in the cells are constant, i.e., isogenomic,
where the only variables between strains are the RE sequence, WT
or mutant p53 and level of expression.
The luciferase reporter provided a quantitative estimate of
transactivation capacity of WT p53 from the various REs in
cultures of logarithmically growing cells. The strength of
transactivation (relative light units/mg protein) from each RE
were compared to transactivation from the strongly transactivated
p21-59 RE at high p53 expression (0.024% galactose). An example
of transactivation capacity of p53 over a range of expression is
shown by the quantitative assessment of p53-induced transactiva-
tion from the p21-59 RE in vivo (Figure 1C). Functional assessment
with the luciferase reporter assay provided an indication of the
kinetics of transactivation with a basal level of transactivation at
0.00% galactose (2% raffinose), initial induction of transactivation
(between 0.004–0.008% galactose) and maximal level of transacti-
vation (between 0.016–0.024% galactose).
Figure 1. Isogenomic diploid yeast system to investigate transcriptional capacity of p53 towards many REs at various p53 levels. (A)
Transactivation capacities of p53 (WT or mutant) from cognate REs were determined using diploid strains derived from haploids where p53 and
reporters with upstream REs were integrated into different chromosomal loci. Within the p53-host strains, p53 (WT or mutant) was controlled by a
‘‘rheostatable’’ GAL1 promoter (blue cells) (previously described [109]) which allows for controlled, inducible expression of p53. Reporter strains
contained promoter REs upstream of the minimal CYC1 promoter and either the ADE2 color reporter (REP) or the firefly luciferase reporter (tan cells)
[28]. Mating of the REP and p53-host strains results in isogenomic diploid yeast that provide for rapid assessment of the transactivation potential for
WT or mutant p53 proteins towards many individual REs in the p53 transcriptional network [14]. (B) Inducible expression of p53 under the
rheostatable GAL1 promoter. The GAL1 promoter allows for controlled expression of p53 depending on the level of galactose in the media. Raffinose
was added to provide a basal level of expression, as the GAL1 promoter is derepressed, but not induced in media containing this carbon source.
Presented is a Western blot analysis of p53 expression 24 hours post-inoculation with raffinose or raffinose plus increasing amounts of galactose
(0.004–0.032%). Increases in galactose from 0–0.032% correlated with an increase in p53 over a 100-fold range. The p53 protein was detected with
DO-1 and pAb1801 antibodies. The asterisk (*) depicts a longer exposure to reveal protein at basal and lower galactose levels. GAPDH, identified by
immunodetection provided a standard loading control. (C) Quantitative assessment of p53-induced transactivation from the p21-59 RE in vivo. The
diploid yeast strain containing GAL1::WT p53 crossed with the p21-59 RE-luciferase REP was grown overnight in complete medium, diluted, washed
and inoculated into selective medium containing either raffinose or raffinose plus increasing galactose (0–0.032%) for 24 hours. Protein lysates were
obtained and a luciferase assay was used to determine the transactivation capacity of p53 from the p21-59 RE. The strength of transactivation was
calculated as relative light units/mg protein. Circled are the basal, linear-increase, and plateau phases of the transactivation response as a function of
galactose concentration and are referred to as basal, moderate and high levels of p53 expression.
doi:10.1371/journal.pgen.1000104.g001
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Lead to Synergistic Transactivation
A common feature of many p53 target genes, including p21,
PUMA, BAX, and DDB2 (p48), is the presence of multiple p53
binding sites [50–56]. The distance between binding sites is
variable and can even be overlapping. The Mdm2 gene, which
targets p53 for degradation by the ubiquitination pathway through
a negative feedback loop, is an example of a p53 target gene that
contains two promoters. The upstream promoter is constitutively
active and does not rely on p53 for transactivation, whereas the
second is in the first intron and is p53-dependent [57,58]. The
second promoter contains two full-site p53 REs separated by 17
nucleotides (nt). Using our diploid yeast-based p53 rheostatable
system, we investigated the interaction between these two REs and
the impact of this spacer by changing the distance between the
murine MDM2 REs.
The induction from the individual MDM2 REs at high p53
expression was much weaker than observed with the strong p21-59
RE (Figure 2A): ,33% (RE1) and ,18% (RE2) relative to p21-59
RE. However, transactivation from the natural MDM2, containing
the 17 base spacer, was much higher than the sum of the individual
REs, reaching the p21-59 RE levels. The synergy was apparent at
both moderate and high p53 levels. To determine the impact that a
spacer may play for full-site REs, the distance was reduced to either
10 or 5 nt. As shown in Figure 2B, decreasing the separation to
10 nt had little effect. However, a decrease to 5 nt resulted in a
substantial reduction in transactivation suggesting that synergistic
interactions are lost as full REs become closely spaced, although
transactivation from the two sites remain additive.
Increase in Spacer between Half-Sites Decreases p53
Transactivation
While weak full-site REs can interact synergistically when
separated by 17 bases, previous studies have indicated that spacers
between decamer half-sites of the canonical consensus RE can alter
the ability of p53 to transactivate from a RE [18,59,60]. We
systematically investigated the role that spacers may play on p53
transactivation using the yeast-based rheostatable promoter and a
system based on expression following transfection into human cells.
Addition of a one-base spacer between the p21-59 half-sites resulted
in a dramatic 60% decrease in p53 transactivation (Figure 3A) in
yeast. Addition of a second nucleotide further decreased p53
transactivation to approximately 25% of transactivation at high p53
expression. Importantly, at lower p53 levels transactivation was
essentially abolished, demonstrating that the impact of spacer is
markedly affected by p53 expression level. Further increases in
spacer resulted in decreased transactivation and at 5 nt there was
almost no detectable luciferase activity at highp53expression levels.
Similar findings were observed in a plasmid-based haploid yeast
system when p53 transactivation was measured from p21-59 REs
containinga spacerof 0, 2, 5, or 10 nt (Figure S2A) [3,28,30]. Thus,
the length of spacer sequence between decamer half-sites combined
withlevelofp53, greatlyinfluences the abilityofp53to transactivate
from the p21-59 sequence. Interestingly, transactivation by the p53
family members p63b and p73b was also compromised when p21-
59 RE contained spacers (Figure S2B); a 2 nt spacer essentially
abolished transactivation.
To determine the effect of spacers upon weak target REs in the
p53 transcriptional network, transactivation was assessed from the
RE of the human apopotosis gene Noxa [61] with and without a
5 nt spacer between the decamer half-sites. In comparison to the
p21-59 RE, transactivation from the Noxa RE was ,30% of the
levels of p21-59 at high p53 expression (Figure 3A). This was
comparable to p53 transactivation from the p21-59 RE containing
a spacer of 1 or 2 bases. A spacer of 5 bases between the Noxa
half-sites abolished p53 responsiveness (also found with the haploid
yeast system; Figure S2A).
Finally, we wanted to establish the impact that naturally
occurring spacers in REs might have on transactivation. TIGAR
(TP53 induced glycolysis and apoptosis regulator) contains a p53
target RE with a two-base spacer between decamers. This gene
Figure 2. Weak REs can function synergistically when separat-
ed by a spacer. (A) To ascertain if p53 functions from the two full-site
REs of MDM2 independently or if the REs interact, p53 transactivation
from the isolated REs, as well as the natural MDM2 RE containing a 17
nucleotide spacer were evaluated. Isogenomic diploid yeast strains
containing the p21-59 and MDM2 REs, as indicated, were grown in
increasing concentrations of galactose to induce p53 protein to basal,
moderate and high levels of expression. The ability of WT p53 to
transactivate from RE sequences was measured by a luciferase assay
24 hours after inoculation into the galactose supplemented media.
Induction from each RE was compared relative to the ability of p53 to
transactivate from the p21-59 RE at 0.024% galactose and is depicted as
the mean and standard error of measurement (SEM) of 6 independent
experiments. The average light units/mg protein from p21-59 at 0.024%
galactose was 2.1 million. Solid arrows over the sequences indicate a
J-binding site. (B) Impact of reducing the spacer to 10 and 5
nucleotides. The average light units/mg protein for p21-59 at 0.024%
galactose was 2,800,000.
doi:10.1371/journal.pgen.1000104.g002
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PLoS Genetics | www.plosgenetics.org 4 June 2008 | Volume 4 | Issue 6 | e1000104Figure 3. Spacer decreases p53 transactivation, promoter occupancy and binding in yeast and mammalian cells and in vitro. (A)
Transactivation in yeast. The ability of p53 to transactivate from REs containing spacers of variable nucleotide length sequences was measured
24 hours after p53 induction with a quantitative luciferase assay. Induction from each RE at various p53 expression levels were compared to the
induction from the p21-59 RE at 0.024% galactose. The average light units/mg protein for WT p53 towards p21-59 at 0.024% galactose for a minimum
of 6 biological repeats was 1.26 million. *indicates the number of nucleotides in the spacer of the natural RE. Solid arrows identify a J-binding site.
(B) Human SaOS2 cells were transfected with p21-59::luciferase reporter constructs containing spacers of increasing length between decamer half-
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and attenuates the apoptotic response [62–64]. Interestingly, the
natural TIGAR RE is one of the few examples in the genome
where the binding element matches the canonical p53 consensus
sequence precisely (i.e., no mismatches). However, p53 could only
induce transactivation from this sequence to ,20% of the levels
with the p21-59 RE, which does not precisely match the consensus
p53 sequence (Figure 3A). When the spacer was removed, p53
could transactivate from TIGAR to levels comparable to the p21-
59 RE. Similar results were obtained with the haploid yeast system
(Figure S2A).
The impact of spacers on the ability of p53 to function from a
RE was also assessed in human cells under conditions of high p53
expression. Luciferase reporter vectors containing the p21-59 RE
with spacers of increasing length were generated in the vector
pGL3 promoter (pGL3-P). The ability to transactivate from
transfected p21-59 REs was assessed in p53 null SaOS2 cells
(derived from a human osteosarcoma line) that were transfected
with a cytomegalovirus (CMV) based p53 expression plasmid [65].
Consistent with the results observed in yeast, p53-dependent
transactivation decreased with increasing spacer length between
decamer half-sites. As shown in Figure 3B, expression of WT p53
resulted in an ,35-fold induction of transcription from the natural
p21-59 RE as compared to transfection with a p53 deficient
plasmid, whereas transactivation from the p21-59 RE containing a
one- or two-base spacer resulted in a 45% and 67% reduction in
relative luciferase activity, respectively. Similar to the situation in
yeast, additional nucleotides resulted in .90% net reduction in
transactivation. It is interesting that within the three systems–
haploid and diploid yeast and human cells–transactivation from a
RE with a spacer of 10 bases was slightly increased in comparison
to a RE with a 5 base spacer.
Spacers between Half-Sites Impact p53 Binding in vivo
and in vitro
To determine if the difference in p53-dependent transactivation
from REs containing spacers is simply due to a reduction in p53
promoter binding, we investigated in vivo occupancy using
chromatin immunoprecipitation (ChIP) assays and in vitro binding
using a newly developed microsphere binding assay (Noureddine
et al., submitted). ChIP assays were performed on the luciferase
reporter plasmids containing the p21-59 RE with spacers of
varying lengths which had been transfected into SaOS2 cells along
with the p53-expressing plasmid. As shown in Figure 3C, a one nt
spacer decreased occupancy at the p21-59 RE by two-fold. Further
increases in spacer length reduced p53 occupancy. No occupancy
was observed in mock-transfected cells. Thus, the pattern of
occupancy by p53 mirrored that for transactivation. Consistent
with the transactivation results, p53 occupancy at the p21-59 RE
with a spacer of 10 nucleotides was slightly increased in
comparison with a spacer of 5 nucleotides (0.6% vs. 0.4%).
To further characterize the impact of spacer on p53 interactions
with a RE, we utilized a fluorescent microsphere binding assay to
evaluate sequence-specific p53-DNA binding interactions (Nour-
eddine et al., submitted). Briefly, this assay addresses p53 binding
to individual beads with specific RE test sequences, where each
bead ‘‘type’’ (i.e., beads with specific REs) is identified with a
unique double stranded oligonucleotide 24-nt ‘‘tag’’ sequence.
Several bead types are then multiplexed in a binding assay and
analyzed using Luminex technology to determine the amount of
p53 bound to each bead type. We generated a series of oligos with
the p21-59 RE sequence of interest that contained various spacer
lengths flanked by non-specific DNA. Each of these RE sequences
was conjugated to beads. The bead types were combined and
incubated for 60 minutes with nuclear cell extracts obtained from
human lymphoblastoid cell lines that were either not induced or
induced for p53 expression with doxorubicin (Dox). The level of
p53 expression was approximately 15-fold greater in extracts from
Dox-treated versus nontreated cells (data not shown). The p53
interaction with each bead type (i.e., each p21-59 RE variant) was
determined after incubation with p53 antibodies and secondary
antibodies conjugated with phycoerythrin.
As displayed in Figure 3D, the mean relative binding of p53 to
the p21-59 RE with a spacer of 1 nucleotide (0.8360.09) was
comparable to that for the p21-59 RE (1.060.11) with no spacer.
However, p53 binding to the p21-59 REs was affected when the
spacer between half-sites was $2 nucleotides, with a dramatic
decrease at .4 nucleotides. The sequence of the spacer used to
increase the distance between the decamer half-sites had no
apparent effect on binding activity (data not shown). Furthermore,
p53 did not bind to the negative control (NC) sequence which had
the p21-59 RE replaced with a scrambled sequence. Interestingly,
p53 displayed the same residual binding to the individual half-sites
of the p21-59 RE [p21-59 left (L) and right (R)] as it did towards
REs containing a spacer of 4 nucleotides or more (0.06 and 0.08,
respectively).
p53 Can Transactivate from Half-Site REs in Yeast and
Human Cells
Since a low level of binding or transactivation was observed with
widely separated decamers, we investigated p53 binding and
transactivation from single decamer sequences in the yeast diploid
and human cell systems. Transactivation was barely detectable
from the left or right decamers of the p21-59 RE (Figure 4A).
However, two additional complete consensus half-sites, designated
Con G and Con D, were able to support transactivation at a level
corresponding to 2.4% and ,10%, respectively, of that from the
full p21-59 RE. Importantly, transactivation was only observed at
high levels of p53 expression. By way of comparison, transactiva-
tion from the con D half-site was comparable to levels obtained
from the low-responding 14-3-3s RE.
To assess the ability of p53 to transactivate from decamer half-
sites in a mammalian system, luciferase reporter vectors containing
sites in the presence (solid bars) or absence (open bars) of the high expressing pCMV-p53 WT vector. At 48 hours post transfection, induction of the
luciferase reporter was assessed. Relative luciferase activity was compared to the pGL3-P plasmid lacking the p53 RE (mock) and is represented by the
average and standard deviations of three independent experiments, each containing three replicates. (C) Occupancy of p53 at p21-59 REs in human
cells. The p21-59 promoter constructs containing the increasing spacers between half-sites were co-transfected with p53 into SaOS2 cells (as
described in (B)). Twenty-four hours later, ChIP analysis was performed. Presented are the average and standard deviation from 4 independent
experiments (left). PCR products of the Input DNA (input) and ChIP DNA (p53, IgG, or no antibody, Ab) are shown (right). The ‘‘M’’ corresponds to a
pGL3-P plasmid control lacking the p53 RE. No bands were observed above the 600 bp markers. (D) In vitro fluorescent microsphere binding assay to
evaluate sequence-specific p53-DNA binding interactions (see Materials and Methods). Fluorescent microspheres bearing double stranded DNA
fragments were multiplexed and incubated in the presence of nuclear extracts from non-treated (NT) or Doxo-treated (0.6 ug/mL [1 mM]
Doxorubicin for 18 hours at 37uC) lymphoblastoid cells. The DNA fragments contained the p21-59 RE, p21-59 RE with spacers of increasing length (0–
15), p21-59 half-site RE (left or right), or a scramble sequence.
doi:10.1371/journal.pgen.1000104.g003
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Transactivation from decamer REs in the diploid yeast was quantified with a luciferase assay. Protein lysates were obtained 24 hours post inoculation
into galactose supplemented media. The average light units/mg protein for WT p53 towards p21-59 at 0.024% galactose for six biological repeats was
1.8 million. Solid arrows indicate J-binding sites. Comparisons were made with transactivation from the p21-59 full site at high protein levels. (B)
Transactivation in human SaOS2 cells. The cells were co-transfected with WT p53 along with either the full, left or right half-sites of the p21-59 RE
containing reporter construct. Transactivation was assessed with the luciferase assay 48 hours later. Relative luciferase activity was compared toa
mock transfection containing the promoter-less pGL3 plasmid. Presented are the averages and standard deviations of 3 independent experiments
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without a vector containing p53 under the CMV promoter into
p53 null SaOS2 cells [65]. As shown in Figure 4B (also see
Figure 3B), WT p53 induced transactivation from the full p21-59
RE was 35-fold greater than with an empty pGL3-P vector.
However, there was clear induction from the left and right half-
sites, 4- and 6-fold, respectively. These results correlated well with
the relative p53 occupancy assessed by ChIP: 4% for the full RE,
0.4% for the left decamer and 0.9% for the right decamer and
agree with the previous findings in Menendez et al. [66] that p53
can function from a half-site RE. Based on these findings, the p53
transcriptional network may incorporate more downstream targets
than previously predicted.
p53 Transactivation from Decamer Half-Sites Is
Sequence-Dependent
The sequence requirements for p53-dependent transactivation
were examined further, utilizing a plasmid-based haploid yeast
system with rheostatable p53 expression (previously used to assess
transactivation capacity of canonical full-site REs; see Materials
and Methods and [30]). Similar to results from mammalian cells,
p53 was able to weakly transactivate from p21-59 half-site REs at a
level that was ,1% of the levels of transactivation from the p21-59
full-site RE (Figure 4C). This result differed somewhat from that of
the diploid yeast system where transactivation from the p21-59
half-site REs was ,0.5% of the transactivation from the full-length
p21-59 RE (Figure 4A). Transactivation from Con D was greater
than p53 transactivation from either of the p21-59 half-sites and
Con D was greater than Con G in both systems.
We also examined the impact of changes in the WW of the core
CWWG (W=A or T). The 3 bases on either side consisted of
GGG and TCC which had been shown to enhance binding at full-
site REs [33] (Figure 4C). Decamers required the central CATG
motif at the junction of the monomer binding sites for modest
levels of transactivation, ,7% of the levels from the p21-59 RE
(Figure 4C). Altering the motif from CATG to CAAG or CTTG
decreased transactivation another 2- to 3-fold whereas changing
this motif to CTAG nearly eliminated transactivation.
Transactivation was also assessed with various combinations of
sequences surrounding the CATG core domain. As shown in
Figure 4C, transactivation with the GGG/CCC flanking sequence
was comparable to the GGG/TCC sequence tested with the
CWWG motifs. However, transactivation was reduced when other
alterations were made. For example, a change in flanking
sequence to GGG/CTC or GGA/CTC resulted in almost no
transactivation.
p53 Functionality from Noncanonical, L-Site REs in Yeast
We also addressed the ability of p53 to transactivate from L-site
REs. A consensus (Con) binding site was created for each of the
two possible configurations of a L-site RE. The first, designated
Con J, consists of a J-site directly adjacent to a K-site, whereas
the second, designated Con K, contains a 5 base spacer between
the J-site and the K-site. Transactivation in the diploid yeast
system from the Con J and Con K L-site REs was 25% and 18%,
respectively, of the full p21-59 RE level (Figure 5A), at high p53
expression (0.024% galactose). This was substantially more than
observed for half-site REs. Similar findings were observed in the
haploid yeast system (Figure S3A). Further evaluation of the
sequence requirements for p53 transactivation from L-sites with
the haploid yeast system showed p53 could transactivate from a
L-site RE containing a CTTG core (Figure S3B). Transactivation
was also effected by surrounding flanking sequences.
Canonical REs Containing Spacers May Actually Be
Noncanonical L-Site REs
In our examination of full-site RE sequences containing spacers,
several REs contradicted our finding that large spacers between
decamer half-sites abolish p53 transactivation. For example, the
PIDD RE (p53 induced protein with death domain) [67] which
promotes apoptosis has an 8 nt spacer in its RE. Contrary to our
expectation, high expression of WT p53 resulted in ,20% of the
level of transactivation from the p21-59 RE. As expected, removal
of the 8 nt spacer between the decamer half-sites increased the
levels of p53 transactivation (Figure 5B).
Examination of the PIDD RE sequence suggested that rather
than functioning from a canonical full-site RE, p53 might
transactivate from a noncanonical L-site RE. The canonical
PIDD element was first separated into two noncanonical L-site
REs (designated PIDD L A and PIDD L B), both of which
utilized the ‘‘spacer’’ sequence as part of the binding element. The
noncanonical REs were comprised of a J-site directly adjacent to
a K-site, but differed in the central CWWG motif in the half-site
and number of mismatches from the consensus binding sequence.
Transactivation assays revealed p53 could function from the PIDD
L A sequence to levels equivalent to the canonical PIDD RE
containing the 8 nt spacer at high expression (Figure 5B). In
contrast, WT p53 could not transactivate from the PIDD L B RE.
These findings showed that the PIDD RE was neither a true
canonical consensus RE nor an exception to the ‘‘spacer’’ rule, but
rather a noncanonical L-site RE which can support p53
transactivation.
The results of the PIDD RE sequence analysis suggested that
otherknownp53REs previouslyidentifiedascanonical full-site REs
are actually L-site REs. Based on an empirically derived set of RE
rules previously established in our lab to predict p53 transactivation
capacity [14,30,68], several established p53 target REs were re-
examined to determine if their responsiveness to p53 was actually
due to the presence of a noncanonical L-site RE instead of a full-
site RE. As shown in Figure 5C, the REs of p21-39, PCNA, 14-3-3s
(site 2) and Apaf-1 REs were actually comprised of a genuine L-site
binding element (containing a K-site directly adjacent to a J-site)
followed by an additional sequence that vastly deviated from a
consensus J-site. Luciferase assays in the diploid yeast strains
revealed that p53 transactivation from these sites was clearly
reduced in comparison to transactivation of p21-59 RE (Figure 5C),
but comparable to the levels of transactivation from the consensus
L-site REs, Con J and Con K (see Figure 5A). These results are
consistent with p53 transactivation capacities towards the p21-39,
PCNA, and Apaf-1 REs assessed with the haploid yeast system in a
recent study focused on examining conservation of RE sequence
and conservation of RE functionality [68].
that were each done in triplicate. PCR products of the input DNA (input) and ChIP DNA (p53, IgG or no antibody, Ab) are shown (right). Input and
ChIP PCR products for the mock and p21-59 full-site are shown in Figure 3C. No bands were observed above the 600 bp markers. (C) Sequence
dependence of p53 transactivation from decamer half-sites. The extent to which p53 transactivation from half-sites is sequence dependent at high
expression levels (2% galactose) was determined with a plasmid-based haploid yeast system [30]. Relative light units/mg protein from K-sites were
compared to transactivation from the yLFM strain containing the p21-59 full-site RE. The average light units/mg protein from p21-59 at 2% galactose
was 2.9 million.
doi:10.1371/journal.pgen.1000104.g004
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and L-Site REs
We examined several p53 mutations that could address the
structural requirements for transactivation from noncanonical REs
(K-a n dL-site REs) in comparison to canonical REs (weak and
strong full-sites). The following REs were examined: K-site REs
(con G, con B, p21-59 left, and p21-59 right), L-site REs (con J and
con K), as well as weak (TIGAR and Gadd45) and strong (p21-59
and TIGAR-spacer) full-site REs. Mutations in the oligomerization
domain were analyzed for transactivation capacity to determine the
extent to which the tetramerization of p53 facilitated functionality
from noncanonical REs. Also examined were N-terminal transacti-
vation domain and C-terminal regulatory domain mutants. The
results are summarized in Table 1 and presented relative to
transactivationfromthep21-59RE.Thevariationintransactivation
by the p53 mutants towards the REs was not due to differences in
levels of expressed p53 protein (Figure S4).
The Arg337 residue is located on the surface of the
tetramerization domain and plays a role in tetramer stabilization
through a salt bridge with Asp352 on the opposite monomer [69–
73]. The mutations R337C and R337H, associated with Li-
Fraumeni-like syndrome (LFL) and adrenal cortical carcinoma
(ACC), respectively, appear to compromise the ability to form
tetramers. The impact of the R337C mutation (previously
described as a partial function mutation) on p53 functionality
has been postulated to arise by a change in thermodynamic
stability, shifting the equilibrium from the tetramer to dimer and/
or monomeric states [74,75]. The R337H mutation is considered
to have a subtle functional effect causing a pH dependent effect on
folding [69,74,76–79] (Storici and Resnick, unpublished data).
Figure 5. A L-site can function as a noncanonical RE in p53 transactivation. (A) Transactivation was assessed from L REs Con J and Con K.
The ability of WT p53 to transactivate was measured with the diploid yeast luciferase assay 24 hours post inoculation into the galactose-
supplemented media. Induction from each RE was compared relative to the ability of p53 to transactivate from the p21-59 RE at 0.024% galactose and
is depicted as the mean and SEM of 6 independent experiments. The average light units/mg protein from p21-59 at 0.024% galactose was 2.1 million.
Solid arrows indicate a J-binding site. (B) p53 functions from a L-site RE in the PIDD RE. Removal of the natural 8 bp spacer increased
transactivation as expected; however, p53 was also able to transactivate from the natural PIDD RE containing the spacer. To determine the true
functional p53 binding element, the canonical PIDD RE was broken into two noncanonical sites, L PIDD-A and L PIDD-B, which incorporated the
spacer sequence into the RE and assessed for transactivation capacity with the luciferase assay. Solid arrows indicate J-binding site; dashed arrows
indicate putative J-binding sites. (C) Analysis of p53 transactivation from various p53 targets in the genome that may be functioning L-sites. Shown
are the identified p53 target sequences for p21-39, PCNA, 14-3-3s site 2 and APAF1 with the noncanonical L-site RE contained in these sites
(identified by solid arrows).
doi:10.1371/journal.pgen.1000104.g005
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R337C was found to be an altered function mutation in the diploid
yeast and SaOS2 cell systems, significantly diminishing transacti-
vation from both canonical and noncanonical REs. Transactiva-
tion from the strong, full-site REs was reduced to less than 25% of
the levels of WT p53 (‘‘+’’ in Table 1), whereas transactivation
from the weaker full-sites and the L-site REs was barely
detectable (‘‘+/2’’ in Table 1) with no transactivation from the
K-site REs.
Similar to previous results [74], the p53 R337H mutant could
transactivate from the p21-59 RE to levels comparable to WT p53
in the haploid yeast system. However, although R337H could
function from the p21-59 RE in the diploid yeast and SaOS2 cell
transactivation assays, the level was reduced in comparison to WT
p53. Similar results were found for transactivation from the
weaker full-site REs and L-site REs. The differences between WT
and mutant p53 were not as clear for the K-site REs.
L344 is one of five residues that comprise the hydrophobic core
of the a-helices which form the interface for p53 dimer-dimer
interactions [70,72,73,80,81]. The mutation L344A prevents
tetramer formation although stable dimers are formed
[72,80,82,83]. The missense mutation L344P disrupts the helix
[74,84–86] and is associated with Li-Fraumeni syndrome (LFS).
This alteration prevents dimer formation resulting in monomeric
p53 protein [74,75,86–89]. Within the haploid and diploid yeast
systems, the L344A protein had reduced transactivation activity
towards the strong canonical full-site REs and noncanonical L-
site REs (Table 1) and no activity towards half-sites. However, the
L344A protein was capable of transactivating to low levels from
the p21-59 half-site REs within mammalian cells. Similar results
were seen in SaOS2 cells with an N345S dimer mutation, where
transactivation was measurable, but significantly reduced in
comparison to WT p53 transactivation (data not shown).
Consistent with previous findings showing L344P is a loss-of-
binding mutation, the monomeric p53 L344P was not able to
transactivate from the full-site, L-site, or K-site REs tested within
the 2n yeast or SaOS2 cells (Table 1) [74,75,86–89]. Similarly, the
germline mutation L330H, which is predicted to form only
monomers through destabilizing the b-strand of the tetrameriza-
tion domain [80,87,90], was also inactive for transactivation from
Table 1. Transactivation capacity of WT and mutant p53 towards canonical and nncanonical REs.
SYSTEM p53 ALLELE: RE
tetramer altered tetramer dimer monomer terminal D
WT R337C R337H L344A L344P D 368
FULL RE:
1n +++ +++ +/2
a +/2
a +++
2n +++ + + +/2
b 2 ++ p21-59
mammalian +++ + ++ ++
d 2 ++
1n +++ ++ TIGAR
2n +++ + + +/22 +++ no spacer
1n + +/2 TIGAR
2n ++ /2 +/22 2 +/2 natural
1n ++ + Gadd45
2n ++ +/2 +/22 2 +
L RE:
1n ++ + + 2 + Con J
2n ++ +/2 +/2 +/22 +
1n ++ + + 2 +/2 Con K
2n ++ /2 +/2 +/22 +
K RE:
1n +/22 2 +/2 Con G
2n +/22+/22 2 +/2
1n +/22 2 2 Con B
2n +/22+/22 2 +/2
mammalian + [y +/2] 2 +/2 +/22 p21-59 left
mammalian + [y +/2] 2 +/2 +/22 p21-59 right
WT p53 and several structural mutations were examined in three in vivo systems (haploid [1n] and diploid [2n] yeast and human SaOS2 cells) for transactivation from REs
representing full, L-sites and K-sites. The ability of the p53, WT or mutant, to transactivate from a RE was measured with a luciferase assay and compared to the ability
of WT p53 to transactivate from the p21-59 RE at 0.008% and 0.024% galactose in 1n and 2n yeast, respectively, or compared to the pGL3 plasmid lacking the promoter
REs in human cells. Relative transactivation by a p53 variant in comparison to WT p53 towards the p21-59 RE is represented by +++ (75–100%), ++ (25–75%), + (7.5–25%),
+/2 detectable but weak response, or 2 (no detectable response). The R337C and R337H mutations are compromised for their ability to form tetramers (the
equilibrium between dimers and tetramers is altered in comparison to WT p53) [86]. The L344A and L344P mutations result in p53 protein being present as a dimer and
monomer, respectively. The D368 mutation deletes the C-terminal basic domain required for structure-specific and non-sequence specific binding but has no effect on
dimer or tetramer formation. ‘‘a’’ corresponds to significantly higher response at high galactose concentrations (0.128% and 2%). ‘‘b’’ indicates that the mutant was
capable of transactivation from RE in an ADE2 plate assay at high galactose concentrations. ‘‘d’’ indicates that the dimer mutation N345S was also analyzed in the
mammalian system and yielded the same results as L344A.
doi:10.1371/journal.pgen.1000104.t001
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(data not shown).
Finally, deletion of the tetramerization domain (D325–357) or a
terminal truncation (331 stop: similar to the p53b isoform) resulted
in complete loss of transactivation from any of the binding
sequences examined, including full-site REs, in the yeast or SaOS2
cell systems (data not shown). These results were in agreement
with previous findings that the tetramerization region is necessary
for p53 binding to and transactivation from a RE [83,91].
Previously, we reported that the terminal deletion D368 resulted
in reduced transactivation capacity towards full-site REs when
assessed with a yeast ADE2 reporter plate assay (on plates) in
haploid yeast [30]. Those studies have been extended to address its
ability to transactivate from full-, L- and K-site REs. We found
that removal of the C-terminal tail resulted in at most a modest
transactivation from the noncanonical and canonical REs
(Table 1). The inhibition varied with the strength of the RE
sequence, as well as with level of p53 expression (data not shown)
for all REs. Thus, in comparing WT to mutant, the C-terminal
domain of p53 appears in several cases to actually enhance rather
than repress transactivation from canonical, as well as noncano-
nical REs.
Finally, we also examined a deletion in the N-terminal domain,
D1–39, to assess if transactivation from L- and K-site REs was
differentially affected. The mutation resulted in ,25% residual
transactivation from the full-site REs (strong: p21-59 and TIGAR -
spacer; moderate: GADD45) at low expression in the haploid yeast
system (data not shown). At the high expression levels required to
examine noncanonical REs (0.128% galactose), transactivation
was also reduced from L-site REs (con J and con K) and a K-site
RE (con G) suggesting that the canonical and noncanonical REs
are similarly affected by defects in the transactivation domain.
Discussion
Given the role for p53 in assuring genome stability, it is
important to understand how this master regulator functions as a
sequence-specific transcription factor. The interactions of p53
bound to DNA, as well as the mechanisms by which WT or
mutant p53 can transactivate to different extents from the many
variants of the consensus motif are not completely understood. In
this work, we have developed a matrix of factors influencing
transactivation that include WT and mutants, sequence and motif,
and DNA binding. We have established that p53 can function
from many noncanonical K- and L-site REs that are common to
the genome. Importantly, functionality of a sequence is not
directly predictable by relation to the consensus sequence.
Isogenomic System To Address p53 Transactivation from
Many REs in Diploid Yeast
Yeast has been extensively used as an in vivo test tube to analyze
p53 transactivation capacities towards p53 response elements
(REs) derived from human genes and assess the potential role that
target sequence plays in p53 functionality [3,14]. A distinct
advantage of yeast is the opportunity to rapidly modify in vivo
either the target REs or to create mutant p53 coding sequences
utilizing a highly efficient recombination-based system, known as
delitto-perfetto [Italian for ‘‘perfect murder’’] that targets desired
changes with oligonucleotides [49,92,93]. The newly developed
diploid yeast approach extends our previous work with a plasmid-
based haploid yeast system in order to capitalize upon the
opportunity to conveniently merge a large number of integrated
(single copy) p53 mutants with transactivation capabilities at many
response elements simply through mating of strains. Not only can
the rheostatable, diploid yeast system differentiate between
functional and nonfunctional REs, it can also estimate weak to
strong functionality at different levels of p53 expression. The
results in yeast have proven useful in guiding studies with highly
expressed WT and mutant p53 towards potential target REs in
human cells and evaluations of direct DNA binding.
Spacers Can Have Opposite Effects on Transactivation
Previous studies have shown that widely-separated full-size REs
associated with the same p53 target gene, such as the muscle
creatine kinase (MCK), can interact to synergistically transactivate
the associated target gene [94]. The mechanism has been
suggested to involve looping out of the intervening DNA so that
multiple p53 tetramers can ‘‘stack’’ and concentrate the basal
transcription machinery [94,95]. While this mechanism of
transactivation may hold for REs separated up to 3 kb, the
synergy was proposed to be lost when the distance was less than 25
bases due to steric hindrance [94], an arrangement that holds for
several p53 target genes including MDM2. We found that p53
could function synergistically from the two weak MDM2 REs
separated by a 17 and 10 nt spacer, but further reduction to 5 nt
resulted in additivity.
Interestingly, the length of the spacer between the two REs
within the promoter of Mdm2 has been conserved between mouse
and human although the sequence of the spacer is 50% diverged.
In the haploid yeast system, p53 was found to function similarly
from the human and murine MDM2 REs in terms of synergistic
transactivation [68]. Given the divergence in the sequence of the
spacer, it is unlikely that an additional transcription factor binding
site would be found in the 17 nucleotides that would allow a
second transcription factor to interact cooperatively with p53 to
induce the observed synergistic transactivation from the two REs.
Instead, there may be a functional conservation that assures the
level of p53-mediated transactivation. This is supported by
sequence analysis across 14 species, corresponding to at least
70 million years of evolution, where 12 had maintained the 17
nucleotide spacer (with varying degrees of sequence divergence)
between RE1 and RE2 (including chimp, rat, rabbit, dog,
elephant, armadillo and hedgehog), while opossum and bat had
a one nucleotide indel [96,97]. From this preliminary search, it
appears that the spacer sequence is under stabilizing selection such
that variations in the length of the spacer which would affect the
ability of p53 to synergistically function from these sites were not
observed. Interestingly, a similar phenomenon, is observed in the
DNA sequences within and between (but not flanking) cis-
regulatory elements of the otx, delta, wnt8, and brachyury genes
where insertions or deletions of random sequence do not occur as
assessed by a comparison between the orthologous cis-regulatory
regions and flanking sequences of the sea urchins, Strongylocentrotus
purpuratus and Lytechinus variegatus [98]. We are currently investi-
gating whether functional conservation of spacer length as a
mechanism for regulating p53 functionality holds with other
closely-spaced full-sized p53 REs.
The impact of the spacer between full-sites acts opposite to that
of a spacer between half-sites. In previous studies, it was proposed
that REs had a ‘‘rotational specificity’’ where spacers between
half-sites could abrogate p53-dependent transactivation if they
were on opposing faces of the DNA helix, but had little impact on
transactivation when the half-sites were on the same face
[18,59,60]. Recently, in electrophoretic mobility shift binding
assays (EMSA), a 2 nt spacer did not significantly alter p53 affinity
(Kd) towards a consensus RE [29]. Furthermore, in a 3D model
derived through cryoelectron microscopy of full length p53, where
p53 dimers are proposed to form through interactions of a-helices
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the best fit RE sequence had a spacer length of 6 nucleotides [99].
These in vitro findings imply if p53 transactivation is primarily
dependent on the ability of p53 to bind target REs, a small spacer
would not affect p53-dependent transactivation.
The effect of spacer upon transactivation from a RE at varying
levels of p53 was first analyzed with the WAF1/Cip1 p21-59 RE.
The present results are in agreement with an earlier report
showing that increases in spacer length of 4 or 14 bases between
half-sites decreases p53 transactivation in yeast [18]. However,
there is no evidence for rotational specificity influencing
transactivation. This is the first demonstration that a spacer of 1
or 2 nt between half-sites can dramatically affect the ability of p53
to transactivate from a RE. Importantly, the impact of spacer on
the ability of p53 to transactivate from a RE is greatly influenced
by the intrinsic potential transactivation strength of the RE, as
shown for NOXA, as well as level of p53 expression. We also
established with the haploid yeast system that a spacer had a
similar negative effect on the ability of p53 family members, p63b
and p73b, to transactivate from a RE.
The biological importance of spacer as a means for affecting
response to p53 was clearly demonstrated for the TIGAR RE. We
propose that unlike the implications from the established
consensus RE, a spacer between half-sites in natural elements
serve to modulate the levels to which p53 can regulate the
associated target gene and may play an important mechanistic role
in the evolution of RE responsiveness to p53. In the case of
TIGAR, the opportunity to address evolutionary implications is
limited due to the apparent recent emergence of the putative p53
binding site in the primate lineage, however, the orthologous
TIGAR RE in Pan troglodytes (chimpanzee), and Macaca mulatta
(rhesus monkey) also contain a 2 nt spacer [96,100].
Binding vs. Transactivation
Several modes of binding have been postulated for p53 to a RE
containing a spacer that include shifting of the tetramer on the
DNA to compensate for the reduced protein-protein interactions,
bending and/or kinking of the DNA within the spacer and/or RE
and rotational motions of p53 to accommodate supercoiling of the
spacer sequence [24,27]. In any of these, binding would modify
either the conformation of the p53 tetramer and/or the DNA
sequence itself in a fashion that is not predictable from current
structural studies. While functional studies demonstrate that the
RE sequence can dramatically influence the level to which p53 can
transactivate from a specific RE [3], the relationship between in
vitro binding and efficiency of in vivo transactivation had not been
established prior to this study.
We utilized a novel fluorescent microsphere, semi-in vitro
binding assay to determine the effect of spacer upon p53 binding.
Recently, we demonstrated a good correspondence between
binding and in vivo transactivation for several human p53 target
REs (Noureddine et al., submitted). While differences were
observed between the in vivo and in vitro assays for p53 binding
to the p21-59 RE containing a single nucleotide spacer, increasing
the length of a spacer between the decamer half-sites beyond one
nucleotide had a large impact on the ability of p53 to bind in the
semi-in vitro assays, contrary to reports with pure components
[22,23]. Interestingly, p53 binding to a RE with a $3 nt spacer
was nearly equivalent to binding to the individual p21-59 half-site
REs, suggesting that p53 may recognize each decamer sequence as
a distinct binding motif once a spacer increases beyond a certain
length. These findings strongly argue that the 0–13 nucleotide
spacer in the established p53 consensus sequence, which is based
on interactions between purified protein and REs, should be
reduced to no more than a few bases. It appears that factors
present in nuclear extracts or cells limit the ability of p53 to
recognize REs with spacers between half sites. It will be interesting
to identify these putative spacer-discriminating factor(s).
p53 Functionality from K-Site and L-Site REs
The observations that p53 can function, as defined by binding
and transactivation, from consensus half-site REs in yeast and from
the p21-59 half-site REs in mammalian cells indicate the p53
transcriptional network is comprised of many more downstream
targets than previously predicted. Transactivation from half-sites is
strongly dependent upon the targeted sequence and level of p53
expression. Similar to full-site REs [30], the central binding motif at
the monomer junction (i.e., CATG) had the greatest impact upon
the ability of p53 to function from half-sites. The difference between
theyeast andmammaliansystemsinfunctionality from thehalf-sites
indicates that additional co-factors in human cells may assist in p53
interactions with weaker binding sequences. Tetrameric p53 can
bind full-site and half-site binding elements in vitro, but the p53
bound to a half-site had a much higher disassociation rate in vitro as
indicated through ‘‘trap’’ assays that had measured dissociation of
p53 from a labeled RE sequence [22].
Given the higher probability of a decamer sequence occurring
in the genome compared to a 20 base sequence, it will be
interesting to determine the number of functional p53 half-site
REs in the human genome which is composed of ,3 billion base
pairs. In a preliminary genomics screen, we have identified over
1,400 ‘‘perfect’’ p53 half-sites containing a CATG core motif in
the genome within 2 kb of a transcriptional start site. However, the
question remains as to which of these sites will have a relevant
biological function in p53-dependent stress responses or whether
the sequences are merely ‘‘noise’’ within the genome.
Half-sites could serve many roles in the genome. For example, a
collection of half-sites could affect chromatin accessibility to
transcriptional machinery (i.e., loosening the chromatin or
recruiting and sequestering chromatin modifiers). Such sites might
function in the proposed opening of the genome to make it more
available for repair [101]. On the other hand, half-sites might also
serve to titrate p53. Additionally, p53 half-sites may play a role in
bringing together different transcriptional networks as described
for a SNP in the FLT-1 promoter [41,66]. Subsequent studies of
the FLT-1 half-site have shown that p53 bound to the T-SNP can
cooperate with estrogen receptor (ER), also bound to a half-site of
its own consensus sequence, to synergistically transactivate from
the FLT-1 T promoter [66]. Such co-regulation may be
advantageous for precise fine-tuning of p53-regulated responses
and may make activity from the noncanonical K-site REs more
dependent on availability of cooperating transcription factors or
additional cofactors and on levels of nuclear p53.
Within yeast, p53 was able to transactivate from noncanonical
consensus L-site REs containing a J-site adjacent to a K-site or
a J-site separated from a K-site by a 5 nt spacer. The lack of a
significant difference between the transactivation from both L-site
REs imply that p53 encounters the L-site RE as a tetramer
protein. Transactivation from L-site REs was moderate relative to
full-sites. Furthermore, the hierarchy of transactivation, in terms of
the level to which p53 could bind and transactivate in vivo, was
comparable to earlier in vitro studies that measured p53 binding
efficiencies towards K-sites, L-sites and full-site sequences with
competitive gel retardation assays [59]. The impact of a L-site
was revealed in our study of the RE for the PIDD gene where p53
transactivation was substantial even though the RE contained a
spacer greater than 3 nt. Transactivation assays revealed the
responsiveness of the originally described PIDD RE was actually
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L A RE, but not the PIDD L B reinforces the requirement for a
strong core element for functionality and that a functional RE
cannot contain greater than 3 mismatches within a half-site. There
are likely to be many functional L-site REs in the genome, among
which are sequences that were originally considered as canonical,
full-site REs containing .2 nt spacers. Furthermore, as recently
pointed out in our functional conservation analysis of p53 REs
from several species, there are clear examples of weaker,
apparently noncanonical L-site REs, such as p21-39 and APAF1
being conserved in evolution [68].
While this report is the first to systematically evaluate p53
function from noncanonical K- and L-site REs, there are other
reports of a transcription factor binding to noncanonical binding
sites within the genome. Johnson et al. [102], recently mapped the
in vivo interactome for the transcription factor neuron-restrictor
silencing factor (NRSF) using a large scale ChIP analysis and
found that NRSF bound to noncanonical half-site binding motifs.
A variety of approaches such as ChIPSeq or FAIRE, formalde-
hyde-assisted isolation of regulatory elements, may be able to
reveal interactions at noncanonical sites under different stress
conditions and in various cell types [103,104] to better understand
the dimensions of the p53 master regulatory universe.
Transactivation From K-Site and L-Site REs Require
Tetrameric p53
Having established WT p53 interacts with sequences that do not
fully conform to the canonical p53 binding sequence, a panel of
p53 mutants was analyzed to determine what structural features of
p53 play a role in transactivation from K- and L-site REs versus
full-site REs. Together, the mutations suggest that common
functional aspects of p53 are required for the ability of p53 to
function from full, L-, and K-site REs. In general, the observed
transactivation of oligomerization mutations towards full-site REs
was in agreement with previous reports of mutants able to form
tetramers or dimers retaining transactivation towards strong REs,
while monomeric proteins were inactive [89].
Having established WT p53 interacts with noncanonical
sequences, a panel of p53 mutations was analyzed to determine
what structural features of p53 play a role in transactivation from
K-site and L-site REs versus full-site REs. The observed
transactivation of oligomerization mutations towards full-site REs
has confirmed previous reports of mutants able to form tetramers or
dimers retaining transactivation towards strong REs, while
monomeric proteins were inactive [89]. Together, the mutations
suggest that common functional aspects of p53 are required for the
ability of p53 to function from full, L-, and K-site REs.
The DNA binding domain of p53 has been shown in vitro to
bind DNA in the absence of the oligomerization domain and that
dimeric p53 can bind to half-sites in a cooperative fashion
independent of tetramerization [22,105]. While able to transacti-
vate at a low level from strong full-site REs and L-site REs, the
L344A dimerization mutation was unable to transactivate from the
weak full-site REs or consensus half-site REs in yeast. In
agreement with these findings, Waterman et al. previously showed
that the L344A protein could bind in vitro to oligonucleotides
containing an optimal consensus binding site and/or half-site, but
not to an oligonucleotide containing a suboptimal full-site [83].
The impact of the dimer mutation L344A, as well as N345S,
was less severe in mammalian cells. Similarly, a designed dimer
mutant (Met340Gln/Leu344Arg) was capable of transactivating
from a p21 full-size RE within SaOS2 cells to half the level of WT
p53 suggesting a direct correlation between the oligomeric state
and transactivation activity [75]. While L344A dimeric proteins
may bind to the sites in a cooperative fashion, tetramerization
which is a necessity for efficient transactivation may be required to
stabilize the binding and reduce the off-rate of p53 from the DNA
in yeast. It is possible that other factors in SaOS2 cells may
contribute to this stabilization accounting for the difference
between the systems.
Since altered tetramer proteins and dimers exhibited a reduced
ability to transactivate from noncanonical REs, transactivation is
not simply an additive process determined by the number of
available pentamer sequences. It is possible that binding and
transactivation in vivo, but not binding alone, may require a
conformational change of the p53 protein that is only obtainable
with a tetrameric protein. Several transcription factors have
displayed such a characteristic including the heat shock protein
which can bind chromatin weakly as monomer, but is not
sufficiently active to cause a biological response until after it is
induced and forms a trimer [106,107]. Furthermore, in the case of
a half-site, where there is not a sequence to which the second p53
dimer can bind, tetramerization may assure the second dimer is in
the vicinity of the p53 binding element in order to interact with
other factors required for transactivation.
The finding that the p53 D368 mutation reduced transactiva-
tion from both canonical and noncanonical REs agrees with
studies showing that p53 does not require modification of the C-
terminal to engage its target binding sites [31,32]. Furthermore,
these results indicate that the C-terminal is not absolutely essential
for function from canonical or noncanonical sites, but may play a
role in regulating the level of transactivation.
The deletion of the first N-terminal transactivation domain
(TAD) which mimics a naturally occurring alternatively spliced
form of p53 that is differentially expressed in breast tumors, had a
more severe impact upon transactivation than previously reported
with the qualitative ADE2 color reporter (data not shown)
[30,108]. The results may reflect the greater quantitative
assessment of transactivation with the luciferase assay. Neverthe-
less, both assays revealed that the decreased opportunity to
interact with the transcriptional machinery through the loss of the
transactivation domain strongly affects p53 transactivation from
both canonical and noncanonical REs.
Conclusions and Implications
Through deconstructing the canonical consensus sequence and
assessing functionality, as determined by binding and transactiva-
tion within three in vivo model systems and a semi-in vitro binding
assay, it has been possible to refine the requirements for functional
p53 binding elements. The organization and arrangement of
binding motifs, as well as the level of p53 expression, have a large
impact on the ability of p53 to transactivate from a RE sequence.
It is interesting that p53 may not function from reported canonical
consensus REs yet functions from noncanonical REs that are
common to the human genome. Half-sites and spacers between
full-sites may provide additional levels of regulation in p53
transcriptional network. Truly functional REs may be restricted to
decamers separated by ,3 nucleotides. When the spacer increases
beyond 3 nucleotides, we suggest p53 recognizes the half-sites as
separate binding entities.
The ability of p53 to function from noncanonical decamer half-
sites introduces a new realm of target sequences and genes into the
p53 transcriptional network and expands the universe of p53
regulated genes. Noncanonical sequences might provide p53
responsiveness at high levels of expression or in combination with
other transcription factors, as for the case of the FLT-1 gene [66].
As discussed in the ‘‘piano model’’ for transactivation from a
broad range of REs [14], variation in the level of p53, as well as
Noncanonical DNA Targets of p53
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responses. Determining the relationship between expression levels
and responsiveness at canonical and noncanonical target sequenc-
es is important in understanding how p53 implements cellular fate
in response to stress, such as cell cycle arrest or apoptosis. It is also
important for addressing the consequences of p53 alterations,
particularly those mutations that retain transactivation capabilities,
as well tailoring individual therapies.
Materials and Methods
Construction of Isogenomic Diploid Yeast Strains
Containing p53 Inducible Reporters
The site-directed mutagenesis system, delitto perfetto [48,49] was
used to generate a panel of isogenic ‘‘p53-host’’ strains and a panel
of response element (RE) reporter strains in the budding yeast, S.
cerevisiae. Each ‘‘p53-host’’ strain, yAT-iGAL::p53 (MATa leu2-
3,112 trpl-1 his3-11,15 can 1-100 ura3-1, trp5::pGAL1:p53:cyc1-Ter,
lys2::Hygro
R), contains the wild type p53 cDNA controlled by the
inducible, ‘‘rheostatable’’ GAL1 promoter [109] integrated at the
TRP5 locus on chromosome VII. p53 mutations in the
tetramerization and basic domains were constructed using a
derivative of the p53 host strain containing a CORE cassette (CO,
counterselectable, KLURA3; RE, reporter, KanMX4 resistance
gene) integrated within the p53 cDNA at nucleotide position 1105
[110]. Modification of the p53 cDNA was performed using the
delitto perfetto approach [48,49] where the CORE cassette was
replaced with an oligonucleotide containing the mutation of
interest to generate a full-length mutant p53 cDNA or the desired
deletion of the C-terminus. Replacement of the CORE was
confirmed by selection on 5-FOA and kanamycin sensitivity.
Specific p53 alterations were confirmed by colony PCR and
sequencing (Big dye, Applied Biosystems, Foster City, CA).
The second panel of isogenic strains containing p53 REs
upstream of the CYCl minimal promoter and the firefly luciferase
reporter were obtained starting from the yLFM-ICORE strain, as
previously described (Table S1) [42]. The reporter strains are also
isogenic with the p53 host strains, but LYS2 and Hygro
s.
Mating of the reporter and p53-host strains followed by
selection for diploid cells on Lys2 Hygro+ plates, results in
isogenomic yeast that enable the assessment of the transactivation
potential for WT or mutant p53 proteins towards individual REs
in the p53 transcriptional network. Strains differ only by the
mutation of interest and 4–5 nucleotide variation in the RE.
Quantitative Luciferase Assay in Diploid Yeast
Individual p53-inducible RE reporter colonies were inoculated
into 5 ml rich media, YPDA plus adenine [200 mg/L], and grown
overnight at 30uC with shaking. The overnight culture was diluted
1:50 in H2O. For each reaction, 1 ml of the diluted culture was
spun down, washed of residual glucose with H2O and re-
suspended in 2 mL synthetic complete - LYS media containing
2% raffinose or raffinose supplemented with either 0.008% or
0.024% galactose. These dilute raffinose cultures were grown
overnight (,18 hr) at 30uCt o,2–4610
7 per ml. The 2 ml
cultures were spun down and the supernatant was aspirated. The
remaining pellet was resuspended in 100 ml reporter lysis buffer
(Promega, Madison, WI) and an equivalent amount of 425–
600 micron acid-washed, glass beads was added (Sigma, St. Louis,
MO). Samples were homogenized for 30 seconds in the Biospec
Products, Inc. mini-bead beater (Bartlesville, OK), briefly
incubated on ice and spun for 20 minutes at 16k relative
centrifugal force (rcf) in an Eppendorf 5415R centrifuge (Batavia,
IL) to separate the soluble protein fraction. The standard protocol
recommended by the manufacturer (Promega; Madison, WI) was
performed for the luciferase assay system starting with 10 mlo f
protein extract. Luciferase activity was measured from 96-well,
white optiplates (Perkin Elmer, Waltham, MA) in a Wallac Victor
2
multilabel counter (Perkin Elmer, Waltham, MA). Light units were
standardized per mg protein as determined by a Bio-Rad protein
assay (Bio-Rad; Hercules, CA). Luciferase assays in haploid strains
were performed as previously reported [14].
Human Cell Lines
Human SaOS2 (HTB-85, ATCC) osteosarcoma cells were
grown in McCoy’s A5 medium supplemented with 10% FBS and
16 penicillin/streptomycin (Gibco, Carlsbad, CA). All cultures
were incubated at 37uC with 5% CO2. Human lymphoblastoid
cells were grown in RPMI 1640 media supplemented with 15%
heat-inactivated fetal bovine serum (Invitrogen, Carlsbad, CA) and
incubated at 5% CO2 at 37uC with 1% penicillin-streptomycin
antibiotics (Invitrogen). The lymphoblast cell lines GM12824 and
GM12825 used in the semi-in vitro binding assay were purchased
from Coriell Cell Repositories (Camden, NJ).
Transfections and Luciferase Assays in Human Cell Lines
Plasmids pC53-SN3 [111] coding for human p53 cDNA under
the control of CMV promoter and the control vector pCMV-Neo-
Bam were kindly provided by Dr. Bert Vogelstein. p53 mutations
within the pC53-SN3 vector were generated by site-directed
mutagenesis (QuickChange site-directed mutagenesis kit, Strata-
gene) and were confirmed by sequencing. Luciferase reporter
constructs containing the p53 REs were constructed in pGL3-
Promoter backbone (Promega, Madison, WI). Partially comple-
mentary oligonucleotides containing the RE and 5 additional
flanking nucleotides from both sides were annealed in vitro to yield
double-stranded molecules that would be compatible for an in vitro
ligation reaction with XhoI/BamHI double digested pGL3-
promoter vector. Ligation products were transformed into XL1
blue E. coli cells, purified, amplified and sequenced. pRL-SV40, a
reporter plasmid coding for Renilla reniformis luciferase (Promega,
Madison, WI) was used as a control of transfection efficiency in the
luciferase reporter assay.
For luciferase assays SaOS2 cells were seeded in 24-well plates
24 hours before transfection. Cells were transfected using Fugene-
6 (Roche, Indianapolis, IN) according to manufacturer’s instruc-
tions at ,80% confluence (with 200 ng of reporter constructs).
When appropriate, 25 ng of the p53 was co-transfected. Total
plasmid DNA per well was adjusted to an equal level by adding the
empty vector pCMV-Neo-Bam. Forty-eight hours post transfec-
tion, extracts were prepared using the Dual Luciferase Assay
System (Promega) following the manufacturer’s protocol and
luciferase activity was measured in a Victor Wallac multilabel
plate reader (PerkinElmer). For each construct, relative luciferase
activity is defined as the mean value of the firefly luciferase/
Renilla luciferase ratios obtained from at least three independent
experiments.
Chromatin Immunoprecipitation (ChIP) Assays
SaOS2 cells were seeded in 10-cm dishes and transfected at
80% confluence with WT p53 expression vector along with the
pGL3-P reporter plasmid containing the p21-59 RE or its
derivatives. ChIP on plasmid assays were performed as described
previously [66] using the ChIP kit (Upstate Biotechnology)
following the manufacturer’s instructions. A mouse monoclonal
anti-p53 antibody DO7 (Pharmigen, BD) was used. PCR
amplifications were performed on immunoprecipitated chromatin
using a pair of primers to amplifya specific region in the pGL3-P
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CAGTGCAA-39 and 59-TGGAATAGCTCAGAGGCCGA-39).
The PCR cycles were as follows: an initial 10 min Taq Gold
polymerase at 95uC followed by 40 cycles of 95uC for 15 s and
60uC for 1 min. The PCR products were then run on a 1.8%
agarose gel and quantified with IMAGEQUANT V5.1 (Molecular
Dynamics-GE, Piscataway, NJ).
Semi-in vitro Binding Assay with Human Nuclear Extracts
To evaluate the sequence-specific p53-DNA binding interac-
tions, we used the semi-in vitro fluorescent microsphere binding
assay as previously described (Noureddine et al., submitted).
Briefly, lymphoblast cells were grown to ,8.5610
5 cells/mL
before exposing to 0.6 ug/mL (1 mM) doxorubicin (Sigma, St.
Louis, MO) for 18 hours at 37uC. Nuclear protein was extracted
from non-treated and treated cells using a Nuclear Extraction Kit
according to manufacturer’s protocol (Active Motif, Carlsbad, CA)
and protein concentration was measured in triplicate using the
BCA Protein Assay Kit (Pierce, Rockford, IL), followed by a plate
read using a Perkin Elmer HTS 7000 BioAssay Reader. All the
oligonucleotides reported in this study were synthesized by
Invitrogen (Carlsbad, CA). Fluorescent microspheres bearing
double stranded DNA fragments containing a sequence of interest
were multiplexed and incubated for 1 hour in the presence of
1.75 mg of nuclear protein extracts from either treated or non-
treated cells. Following incubation in cell extracts, the beads were
incubated with p53 antibodies (DO-7, BD Biosciences, San Jose,
CA) and secondary antibodies conjugated with phycoerythrin(R-
phycoerythrin-coated goat anti-mouse) for 30 minutes. The p53
interaction with each bead was measured on a BioPlex Machine
(BioRad) as raw fluorescence intensity signal generated from
phycoerythrin-conjugated secondary antibody to mouse anti-p53.
For signal normalization, an aliquot of the DNA-conjugated beads
was treated separately with phycoerythrin-conjugated streptavidin
for 20 minutes in the absence of any nuclear extracts. All binding
reactions were conducted in triplicate. For each bead type in every
multiplex set of beads, relative binding signal was obtained by
normalizing the absolute binding signals of extract-treated beads
(mean of 3 replicates) to mean signals obtained from the same set
of beads that were independently treated with phycoerythrin-
conjugated streptavidin (mean of 3 replicates). This normalization
accounts for bead type-specific oligo content. Net binding for each
oligo is the numerical difference between NT and DOX-treated
signal obtained for this oligo.
Western Analysis
Yeast Cells. Individual yAT6yLFM diploid colonies were
inoculated into YPDA media and grown overnight. Overnight
cultures were diluted 1:50 in H2O and 1 ml of the culture was
spun down for each sample treatment, washed with 2 ml of H2O
and inoculated into 2 ml synthetic media (lys-) with either glucose
(2%), raffinose (2%) or raffinose plus increasing amounts of
galactose (0.002–0.032% galactose). Cultures were grown
24 hours at 30uC with vigourous shaking. Protein extracts were
prepared in 35 ml reporter lysis buffer (Promega, Madison, WI)
plus 2% protease inhibitors (cocktail for use with fungal and yeast
extracts; Sigma, St. Louis, MO). An equivalent amount of 425–
600 micron acid-washed, glass beads (Sigma, St. Louis, MO) was
added prior to the samples being homogenized for 30 seconds in
the Biospec Products, Inc. mini-bead beater (Bartlesville, OK).
Following homogenization, samples were briefly incubated on ice
and spun for 20 minutes at 16k rcf in an Eppendorf 5415R
centrifuge (Batavia, IL) to purify soluble proteins. Protein
concentrations were measured with the Bio-Rad protein assay
according to the standard protocol (Bio-Rad; Hercules, CA).
50 mg of total protein extracts were run on SDS-PAGE gels and
transferred as previously described [109]. p53 was detected with
the mouse monoclonal antibodies DO-1 and pAb1802 (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA) according to the
manufacturer’s protocol. GAPDH was detected with the rabbit
polyclonal GAPDH antibody (HRP) (Abcam, Cambridge, MA).
Human Cells. Whole cell extracts from SaOS2 transfected
cells were obtained using cell culture lysis reagent (Promega)
following the manufacturer’s instructions. Equal amounts of whole
cell extracts were separated on 4–12% BisTris NuPAGE and
transferred to polyvinylidene difluoride membranes (Invitrogen).
The blots were probed with primary antibodies (Santa Cruz) for
p53 (pAb1801 and DO-1) and Actin (C-11). Bands were detected
using horseradish peroxide-conjugated secondary antibodies
(Santa Cruz) and the enhanced chemiluminescence (ECL)
detection system (Amersham, Cleveland, OH, USA).
Supporting Information
Figure S1 Low level expression of p53 under the rheostatable
GAL1 promoter. The GAL1 promoter allows for increased
expression of p53 depending on the level of galactose in the
media. With glucose supplemented in the media, the GAL1
promoter is repressed. Raffinose provides a basal level of
expression where the promoter is derepressed, but not induced.
Presented is a Western blot analysis of p53 expression 24 hours
post-inoculation with 2% glucose (G), 2% raffinose (R) or 2%
raffinose plus increasing amounts of galactose (0.002–0.008%).
The p53 protein was detected with DO-1 and pAb1801
antibodies. Immunodetection with GAPDH was used as a
standard loading control. To determine the relative protein
concentrations at repressed, basal and low galactose levels, pixel
values were measured from autoradiographs of increasing
exposure lengths (from 1 to 15 minutes). The ratio of measured
pixel values were calculated between samples and compared
between exposure lengths to derive the relative differences in p53
expression between media containing glucose (2%), raffinose (2%)
or raffinose (2%) plus increasing concentrations of galactose (data
not shown). A 3-fold induction of p53 expression was observed
between samples containing glucose and raffinose, as well as
between raffinose and 0.004% galactose. There was a 2-fold
induction between the 0.004% galactose and 0.006% galactose
samples and a 3-fold difference between the 0.006% and 0.008%
galactose samples. This totaled a relative increase in p53
expression of 54-fold between repressed conditions and induction
at 0.008% galactose and an 18-fold between basal level expression
and induction at 0.008% galactose.
Found at: doi:10.1371/journal.pgen.1000104.s001 (0.48 MB
DOC)
Figure S2 Increase in spacer decreases transactivation by p53
family members. (A) The plasmid-based haploid yeast system [30]
was utilized to determine the extent to which p53 transactivation
was impacted by a spacer between decamer half-sites. Transacti-
vation was measured as relative light units/mg protein at 0.008%
and 0.128% galactose and compared to WT p53 transactivation
from the p21-59 RE. Depicted are the average light units/mg
protein and standard deviations from 3 biological repeats. The
average light units/mg protein for WT p53 towards p21-59 at
0.128% galactose was 2.9 million. (B) The transactivation capacity
of p63b and p73b from the p21-59 RE containing spacers of 0, 2, 5
and 10 nt was measured to determine the affect of spacers on
transactivation by p53 family members. Transactivation was
measured at moderate and high levels of p53 expression.
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Figure S3 Transactivation from noncanonical 3/4-site REs in
haploid yeast. (A) The ability of p53 to transactivate from the
consensus 3/4-site REs, Con J and Con K were determined in the
haploid yeast system, as described in Inga et al. [30]. The ability of
WT p53 to transactivate from the 3/4-site REs was measured
24 hours post inoculation into the galactose-supplemented media
by a luciferase assay. The ability of WT p53 to transactivate from
each 3/4-site RE was compared to the ability of WT p53 to
transactivate from the p21-59 RE at 0.128% galactose. Transacti-
vation is depicted as the light units/mg protein and presented as
the mean and standard deviation of 3 independent experiments.
The average light units/mg protein from p21-59 at 0.128%
galactose was 2.9 million. Solid arrows indicate a 1/4-binding site.
(B) Sequence dependence of p53 transactivation from 3/4-site
REs. The plasmid-based haploid yeast system [30] was utilized to
determine the sequence requirements for transactivation from
noncanonical 3/4-site REs at high expression levels (0.128%
galactose). The central core ‘‘CWWG’’ motif was altered from
CATG to CTTG and flanking regions were changed as described.
Transactivation from 3/4-site REs was measured with a luciferase
assay and calculated as light units/mg protein.
Found at: doi:10.1371/journal.pgen.1000104.s003 (0.51 MB TIF)
Figure S4 Mutant p53 expression. To exclude the possibility
that variation in transactivation capacity towards the canonical
and noncanonical REs by mutant p53 was due to variable protein
levels, the relative expression of p53 mutants was compared to WT
p53. Western analysis was performed 24 hours following transient
transfection of mock, WT p53 or mutant p53 pCMV plasmid
vectors into SaOS2 cells. Thirty-five mg of total protein was run on
4–12% BisTris NuPAGE as described in the Materials and
Methods. Staining of the gel with SimplyBlue SafeStain (Invitro-
gen) for total loading protein was performed to discriminate
possible overlap of protein between the loading control actin and
the truncated p53 protein Q331stop which run at comparable
distances.
Found at: doi:10.1371/journal.pgen.1000104.s004 (2.98 MB TIF)
Table S1 Response element sequences.
Found at: doi:10.1371/journal.pgen.1000104.s005 (0.05 MB
DOC)
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